Zerit (Stavudine, d4T)
| Brand Name: |
Zerit |
| Generic Name: |
Stavudine, d4T |
| Adult Single Dose: |
Patients weighing at least 133 lbs (60 kg): one 40-mg capsule (every 12 hours)
Patients weighing less than 133 lbs (60 kg): one 30-mg capsule (every 12 hours) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- An Overview of Zerit (Stavudine, d4T) (September 13, 2012)
From AIDSinfo
- Zerit (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Patient Information About Zerit (Stavudine, d4T) (PDF) (January 2012)
From Bristol-Myers Squibb Company
- Stavudine (Zerit) (December 17, 2011)
To read PDF, click here.
From AIDS InfoNet
- Zerit (Stavudine, d4T) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- d4T (Stavudine, Zerit) (October 26, 2006)
From AIDS Treatment Data Network
- Zerit (Stavudine) (May 2005)
To read PDF, click here.
From The Center for AIDS
- Drug Interactions: Stavudine (August 2004)
From Project Inform
News
- d4T -- Time to Move On (November/December 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Blog Examines Use of Controversial HIV Drug in Malawi (August 16, 2012)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Stavudine (d4T) Phase-Out Festival in Delhi (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Activists Oppose Gates Foundation Funding Study Using Low-Dose d4T (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Why It's Time to Say Goodbye to Stavudine ... Everywhere (2012)
A group of prominent HIV/AIDS activists and experts argue against any attempt to encourage greater use of Zerit (stavudine).
In Southern African Journal of HIV Medicine
- European Medicines Agency Issues Restricted Indication for d4T (Stavudine) (March/April 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- New Labeling for Zerit Capsules and Zerit for Oral Solution (December 10, 2010)
From U.S. Food and Drug Administration
- New WHO Guidelines Urge Phase-Out of Major HIV Drug (December 1, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- FDA Approval of Three Generic Stavudine Formulations (December 30, 2008)
From U.S. Food and Drug Administration
- Drop d4T From First-Line Therapy, WHO Advises Low-Income Countries – If You Can Afford To (August 8, 2006)
VIEW ALL ARTICLES
Research
- Rapid Drop in Mitochondria in Fat Biopsies Within Four Weeks of d4T Use (November/December 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- High Prevalence of Peripheral Neuropathy in Children Taking d4T in Rural South Africa (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- AIDS 2012: New Drugs and Formulations (August 1, 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- High Prevalence of d4T-Associated Lipodystrophy Including Lipoatrophy in Children (March/April 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- d4T Toxicity Risk 7-Fold Higher When Started With TB Treatment (June 18, 2009)
From aidsmap.com
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From TheBodyPRO.com
- Abacavir Is Not Associated With the Metabolic Changes Seen in Patients Treated With Stavudine (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Both Tenofovir and Stavudine Well Tolerated in HCV-Coinfected Patients (July 12, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
- Micronutrient Supplement Can Improve d4T-, ddI-Related Neuropathy, Study Says (March/April 2004)
In Positively Aware, from Test Positive Aware Network
- Predicting Lipoatrophy After Treatment Initiation (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
